Serum α2-HS glycoprotein concentration in patients with hematological malignancies - A follow-up study

L. Kalabay, K. Cseh, S. Benedek, S. Fekete, T. Masszi, K. Herjeczki, T. Pozsonyi, L. Jakab, L. Jakab

Research output: Article

16 Citations (Scopus)

Abstract

We observed significantly reduced serum α2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum α2-HS glycoprotein levels. The reduction of serum α2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum α2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the α2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.

Original languageEnglish
Pages (from-to)264-269
Number of pages6
JournalAnnals of Hematology
Volume63
Issue number5
DOIs
Publication statusPublished - nov. 1991

Fingerprint

Hematologic Neoplasms
Glycoproteins
Serum
Cytostatic Agents
Leukemia, Myelomonocytic, Chronic
Polycythemia Vera
Primary Myelofibrosis
Blood Sedimentation
B-Cell Chronic Lymphocytic Leukemia
Aspartate Aminotransferases
Multiple Myeloma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Alkaline Phosphatase
Immunoglobulin M
Blood Proteins
Therapeutics
Immunoglobulin G
Liver

ASJC Scopus subject areas

  • Hematology

Cite this

Serum α2-HS glycoprotein concentration in patients with hematological malignancies - A follow-up study. / Kalabay, L.; Cseh, K.; Benedek, S.; Fekete, S.; Masszi, T.; Herjeczki, K.; Pozsonyi, T.; Jakab, L.; Jakab, L.

In: Annals of Hematology, Vol. 63, No. 5, 11.1991, p. 264-269.

Research output: Article

Kalabay, L. ; Cseh, K. ; Benedek, S. ; Fekete, S. ; Masszi, T. ; Herjeczki, K. ; Pozsonyi, T. ; Jakab, L. ; Jakab, L. / Serum α2-HS glycoprotein concentration in patients with hematological malignancies - A follow-up study. In: Annals of Hematology. 1991 ; Vol. 63, No. 5. pp. 264-269.
@article{d800aa5342704a168ad18740100d8177,
title = "Serum α2-HS glycoprotein concentration in patients with hematological malignancies - A follow-up study",
abstract = "We observed significantly reduced serum α2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum α2-HS glycoprotein levels. The reduction of serum α2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum α2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the α2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.",
keywords = "α- HS glycoprotein, Leukemias, Lymphomas, Multiple myeloma, Myelofibrosis, Polycythemia vera",
author = "L. Kalabay and K. Cseh and S. Benedek and S. Fekete and T. Masszi and K. Herjeczki and T. Pozsonyi and L. Jakab and L. Jakab",
year = "1991",
month = "11",
doi = "10.1007/BF01698376",
language = "English",
volume = "63",
pages = "264--269",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Serum α2-HS glycoprotein concentration in patients with hematological malignancies - A follow-up study

AU - Kalabay, L.

AU - Cseh, K.

AU - Benedek, S.

AU - Fekete, S.

AU - Masszi, T.

AU - Herjeczki, K.

AU - Pozsonyi, T.

AU - Jakab, L.

AU - Jakab, L.

PY - 1991/11

Y1 - 1991/11

N2 - We observed significantly reduced serum α2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum α2-HS glycoprotein levels. The reduction of serum α2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum α2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the α2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.

AB - We observed significantly reduced serum α2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum α2-HS glycoprotein levels. The reduction of serum α2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum α2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the α2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.

KW - α- HS glycoprotein

KW - Leukemias

KW - Lymphomas

KW - Multiple myeloma

KW - Myelofibrosis

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=0025949489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025949489&partnerID=8YFLogxK

U2 - 10.1007/BF01698376

DO - 10.1007/BF01698376

M3 - Article

C2 - 1958751

AN - SCOPUS:0025949489

VL - 63

SP - 264

EP - 269

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -